Selected research
Industry Research
Live Attenuated Rotavirus Vaccine Industry Research Report 2026
Market perspective
The global Live Attenuated Rotavirus Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Live Attenuated Rotavirus Vaccine is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Live Attenuated Rotavirus Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Live Attenuated Rotavirus Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Live Attenuated Rotavirus Vaccine include among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Live Attenuated Rotavirus Vaccine market in revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Live Attenuated Rotavirus Vaccine.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Live Attenuated Rotavirus Vaccine Market by Company
Bharat Biotech
GSK
Lanzhou Biological Products Research Institute
Merck Sharp & Dohme
Live Attenuated Rotavirus Vaccine Segment by Type
Monovalent Vaccines
Combination Vaccines
Live Attenuated Rotavirus Vaccine Segment by Application
Hospitals and Clinics
Vaccination Sites
Live Attenuated Rotavirus Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Rotavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Rotavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Rotavirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Live Attenuated Rotavirus Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Live Attenuated Rotavirus Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Live Attenuated Rotavirus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monovalent Vaccines
- Combination Vaccines
Applications
- Hospitals and Clinics
- Vaccination Sites
Companies covered
- Bharat Biotech
- GSK
- Lanzhou Biological Products Research Institute
- Merck Sharp & Dohme
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Live Attenuated Rotavirus Vaccine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Monovalent Vaccines
- 2.2.3 Combination Vaccines
- 2.3 Live Attenuated Rotavirus Vaccine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hospitals and Clinics
- 2.3.3 Vaccination Sites
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Live Attenuated Rotavirus Vaccine Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Live Attenuated Rotavirus Vaccine Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Live Attenuated Rotavirus Vaccine Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Live Attenuated Rotavirus Vaccine Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Live Attenuated Rotavirus Vaccine Production by Manufacturers (2021-2026)
- 3.2 Global Live Attenuated Rotavirus Vaccine Production Value by Manufacturers (2021-2026)
- 3.3 Global Live Attenuated Rotavirus Vaccine Average Price by Manufacturers (2021-2026)
- 3.4 Global Live Attenuated Rotavirus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Live Attenuated Rotavirus Vaccine Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Live Attenuated Rotavirus Vaccine Manufacturers, Product Type & Application
- 3.7 Global Live Attenuated Rotavirus Vaccine Manufacturers Established Date
- 3.8 Global Live Attenuated Rotavirus Vaccine Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bharat Biotech
- 4.1.1 Bharat Biotech Live Attenuated Rotavirus Vaccine Company Information
- 4.1.2 Bharat Biotech Live Attenuated Rotavirus Vaccine Business Overview
- 4.1.3 Bharat Biotech Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 4.1.4 Bharat Biotech Product Portfolio
- 4.1.5 Bharat Biotech Recent Developments
- 4.2 GSK
- 4.2.1 GSK Live Attenuated Rotavirus Vaccine Company Information
- 4.2.2 GSK Live Attenuated Rotavirus Vaccine Business Overview
- 4.2.3 GSK Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 4.2.4 GSK Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Lanzhou Biological Products Research Institute
- 4.3.1 Lanzhou Biological Products Research Institute Live Attenuated Rotavirus Vaccine Company Information
- 4.3.2 Lanzhou Biological Products Research Institute Live Attenuated Rotavirus Vaccine Business Overview
- 4.3.3 Lanzhou Biological Products Research Institute Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 4.3.4 Lanzhou Biological Products Research Institute Product Portfolio
- 4.3.5 Lanzhou Biological Products Research Institute Recent Developments
- 4.4 Merck Sharp & Dohme
- 4.4.1 Merck Sharp & Dohme Live Attenuated Rotavirus Vaccine Company Information
- 4.4.2 Merck Sharp & Dohme Live Attenuated Rotavirus Vaccine Business Overview
- 4.4.3 Merck Sharp & Dohme Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 4.4.4 Merck Sharp & Dohme Product Portfolio
- 4.4.5 Merck Sharp & Dohme Recent Developments
5 Global Live Attenuated Rotavirus Vaccine Production by Region
- 5.1 Global Live Attenuated Rotavirus Vaccine Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Live Attenuated Rotavirus Vaccine Production by Region: 2021-2032
- 5.2.1 Global Live Attenuated Rotavirus Vaccine Production by Region: 2021-2026
- 5.2.2 Global Live Attenuated Rotavirus Vaccine Production Forecast by Region (2027-2032)
- 5.3 Global Live Attenuated Rotavirus Vaccine Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Live Attenuated Rotavirus Vaccine Production Value by Region: 2021-2032
- 5.4.1 Global Live Attenuated Rotavirus Vaccine Production Value by Region: 2021-2026
- 5.4.2 Global Live Attenuated Rotavirus Vaccine Production Value Forecast by Region (2027-2032)
- 5.5 Global Live Attenuated Rotavirus Vaccine Market Price Analysis by Region (2021-2026)
- 5.6 Global Live Attenuated Rotavirus Vaccine Production and Value, YOY Growth
- 5.6.1 North America Live Attenuated Rotavirus Vaccine Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Live Attenuated Rotavirus Vaccine Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Live Attenuated Rotavirus Vaccine Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Live Attenuated Rotavirus Vaccine Production Value Estimates and Forecasts (2021-2032)
6 Global Live Attenuated Rotavirus Vaccine Consumption by Region
- 6.1 Global Live Attenuated Rotavirus Vaccine Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Live Attenuated Rotavirus Vaccine Consumption by Region (2021-2032)
- 6.2.1 Global Live Attenuated Rotavirus Vaccine Consumption by Region: 2021-2026
- 6.2.2 Global Live Attenuated Rotavirus Vaccine Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Live Attenuated Rotavirus Vaccine Production by Type (2021-2032)
- 7.1.1 Global Live Attenuated Rotavirus Vaccine Production by Type (2021-2032) & (Units)
- 7.1.2 Global Live Attenuated Rotavirus Vaccine Production Market Share by Type (2021-2032)
- 7.2 Global Live Attenuated Rotavirus Vaccine Production Value by Type (2021-2032)
- 7.2.1 Global Live Attenuated Rotavirus Vaccine Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Live Attenuated Rotavirus Vaccine Production Value Market Share by Type (2021-2032)
- 7.3 Global Live Attenuated Rotavirus Vaccine Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Live Attenuated Rotavirus Vaccine Production by Application (2021-2032)
- 8.1.1 Global Live Attenuated Rotavirus Vaccine Production by Application (2021-2032) & (Units)
- 8.1.2 Global Live Attenuated Rotavirus Vaccine Production Market Share by Application (2021-2032)
- 8.2 Global Live Attenuated Rotavirus Vaccine Production Value by Application (2021-2032)
- 8.2.1 Global Live Attenuated Rotavirus Vaccine Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Live Attenuated Rotavirus Vaccine Production Value Market Share by Application (2021-2032)
- 8.3 Global Live Attenuated Rotavirus Vaccine Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Live Attenuated Rotavirus Vaccine Value Chain Analysis
- 9.1.1 Live Attenuated Rotavirus Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Live Attenuated Rotavirus Vaccine Production Mode & Process
- 9.2 Live Attenuated Rotavirus Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Live Attenuated Rotavirus Vaccine Distributors
- 9.2.3 Live Attenuated Rotavirus Vaccine Customers
10 Global Live Attenuated Rotavirus Vaccine Analyzing Market Dynamics
- 10.1 Live Attenuated Rotavirus Vaccine Industry Trends
- 10.2 Live Attenuated Rotavirus Vaccine Industry Drivers
- 10.3 Live Attenuated Rotavirus Vaccine Industry Opportunities and Challenges
- 10.4 Live Attenuated Rotavirus Vaccine Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst